{"product_id":"vesugen-20mg-vial","title":"Vesugen 20mg vial","description":"\u003cp data-end=\"459\" data-start=\"67\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"459\" data-start=\"67\"\u003e\u003cstrong data-end=\"78\" data-start=\"67\"\u003eVesugen\u003c\/strong\u003e is a \u003cstrong data-end=\"128\" data-start=\"84\"\u003evascular (“vessel”) peptide bioregulator\u003c\/strong\u003e from the Khavinson\/bioregulation literature, most commonly identified as the \u003cstrong data-end=\"238\" data-start=\"206\"\u003etripeptide KED (Lys-Glu-Asp)\u003c\/strong\u003e. It is described as being derived conceptually from \u003cstrong data-end=\"328\" data-start=\"291\"\u003evascular tissue peptide fractions\u003c\/strong\u003e and later produced as a defined short peptide for research and “bioregulator” product lines. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"709\" data-start=\"461\"\u003e\u003cstrong data-end=\"482\" data-start=\"461\"\u003eRegulatory status\u003c\/strong\u003e\u003cbr\u003eAs marketed in peptide-bioregulator\/supplement ecosystems, Vesugen is \u003cstrong data-end=\"589\" data-start=\"553\"\u003enot an FDA\/EMA-approved medicine\u003c\/strong\u003e with a conventional drug label (standardized indications, PK, contraindications). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"714\" data-start=\"711\"\u003e\n\u003ch2 data-end=\"770\" data-start=\"716\"\u003e2) Biological rationale: why a vascular tripeptide?\u003c\/h2\u003e\n\u003cp data-end=\"1110\" data-start=\"771\"\u003eThe “bioregulator” hypothesis is that \u003cstrong data-end=\"841\" data-start=\"809\"\u003eultrashort peptides (2–4 aa)\u003c\/strong\u003e can influence \u003cstrong data-end=\"897\" data-start=\"856\"\u003ecell phenotype and tissue homeostasis\u003c\/strong\u003eby \u003cstrong data-end=\"931\" data-start=\"901\"\u003emodulating gene expression\u003c\/strong\u003e, potentially via interactions with DNA\/chromatin or promoter regions and by shifting transcriptional programs in tissue-specific cell types. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"1324\" data-start=\"1112\"\u003eFor Vesugen specifically, the strongest mechanistic anchor in the indexed literature is \u003cstrong data-end=\"1248\" data-start=\"1200\"\u003eendothelial cell proliferation\/aging biology\u003c\/strong\u003e tied to \u003cstrong data-end=\"1274\" data-start=\"1257\"\u003eKi-67 (MKI67)\u003c\/strong\u003e regulation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"1329\" data-start=\"1326\"\u003e\n\u003ch2 data-end=\"1424\" data-start=\"1331\"\u003e3) Additional benefits \/ effects under investigation (component-driven; not “drug-proven”)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2924\" data-start=\"1426\"\u003e\n\u003cthead data-end=\"1490\" data-start=\"1426\"\u003e\n\u003ctr data-end=\"1490\" data-start=\"1426\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"1452\" data-start=\"1426\"\u003ePutative benefit domain\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"1490\" data-start=\"1452\"\u003eKey take-aways (evidence-weighted)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2924\" data-start=\"1501\"\u003e\n\u003ctr data-end=\"1866\" data-start=\"1501\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1554\" data-start=\"1501\"\u003e1) Endothelial proliferative capacity during aging\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1866\" data-start=\"1554\"\u003ePeer-indexed work reports that short peptides including \u003cstrong data-end=\"1623\" data-start=\"1612\"\u003evesugen\u003c\/strong\u003e stimulate \u003cstrong data-end=\"1643\" data-start=\"1634\"\u003eKi-67\u003c\/strong\u003e, a proliferation-associated protein that declines with cellular aging in vascular cultures; docking analyses are described for peptide interaction with the \u003cstrong data-end=\"1825\" data-start=\"1800\"\u003eMKI67 promoter region\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2207\" data-start=\"1867\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1919\" data-start=\"1867\"\u003e2) Microcirculatory \/ vascular functional support\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2207\" data-start=\"1919\"\u003eA manufacturer\/brochure source claims Vesugen “normalizes” the functional state of blood\/lymphatic vessels and cites a “clinical study” in complex treatment of atherosclerosis—useful as \u003cem data-end=\"2116\" data-start=\"2107\"\u003econtext\u003c\/em\u003e, but not equivalent to peer-reviewed RCT evidence. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2492\" data-start=\"2208\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2261\" data-start=\"2208\"\u003e3) Epigenetic\/transcriptional regulation framework\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2492\" data-start=\"2261\"\u003eA systematic review on peptide regulation of gene expression places ultrashort peptides like \u003cstrong data-end=\"2363\" data-start=\"2356\"\u003eKED\u003c\/strong\u003e within a broader framework of transcriptional effects and cell differentiation programs. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2924\" data-start=\"2493\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2555\" data-start=\"2493\"\u003e4) Neurovascular\/cognition-adjacent positioning (secondary)\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2924\" data-start=\"2555\"\u003eA review of tripeptides in neuroprotection calls \u003cstrong data-end=\"2623\" data-start=\"2606\"\u003eKED (Vesugen)\u003c\/strong\u003e “vasoprotective” and mentions reported cognitive improvements in a specific occupational cohort after oral administration of KED\/EDR—interesting, but should be treated as \u003cstrong data-end=\"2823\" data-start=\"2795\"\u003elow-to-moderate evidence\u003c\/strong\u003eunless the primary clinical paper is independently reviewed. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"3235\" data-start=\"2926\"\u003e\u003cstrong data-end=\"2952\" data-start=\"2926\"\u003eEvidence quality note:\u003c\/strong\u003e Vesugen’s most defensible scientific foundation is \u003cstrong data-end=\"3049\" data-start=\"3004\"\u003ecell\/culture aging + gene-regulation work\u003c\/strong\u003e. Claims of broad clinical vascular benefit often rely on \u003cstrong data-end=\"3126\" data-start=\"3107\"\u003ebrochure\/vendor\u003c\/strong\u003e sources rather than widely replicated, high-quality randomized trials. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"3240\" data-start=\"3237\"\u003e\n\u003ch2 data-end=\"3277\" data-start=\"3242\"\u003e4) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-end=\"3366\" data-start=\"3279\"\u003e4.1 Target class: not a receptor agonist, but a “gene-regulator” peptide (proposed)\u003c\/h3\u003e\n\u003cp data-end=\"3565\" data-start=\"3367\"\u003eUnlike GLP-1 drugs or monoclonal antibodies, Vesugen\/KED is typically framed as acting through \u003cstrong data-end=\"3498\" data-start=\"3462\"\u003eintracellular\/nuclear mechanisms\u003c\/strong\u003e that influence transcription. System-level descriptions emphasize:\u003c\/p\u003e\n\u003cul data-end=\"3771\" data-start=\"3566\"\u003e\n\u003cli data-end=\"3649\" data-start=\"3566\"\u003e\n\u003cp data-end=\"3649\" data-start=\"3568\"\u003einteraction with \u003cstrong data-end=\"3605\" data-start=\"3585\"\u003epromoter regions\u003c\/strong\u003e (computational docking described), and\/or\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3771\" data-start=\"3650\"\u003e\n\u003cp data-end=\"3771\" data-start=\"3652\"\u003echromatin\/DNA-associated binding patterns that may bias gene expression programs. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3845\" data-start=\"3773\"\u003e4.2 Downstream biology (strongest specific signal: MKI67\/Ki-67 axis)\u003c\/h3\u003e\n\u003cul data-end=\"4165\" data-start=\"3846\"\u003e\n\u003cli data-end=\"3936\" data-start=\"3846\"\u003e\n\u003cp data-end=\"3936\" data-start=\"3848\"\u003e\u003cstrong data-end=\"3865\" data-start=\"3848\"\u003eKi-67 (MKI67)\u003c\/strong\u003e is a marker tightly linked to the active cell cycle (proliferation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4165\" data-start=\"3937\"\u003e\n\u003cp data-end=\"4165\" data-start=\"3939\"\u003eIn the vascular aging work, vesugen is reported to \u003cstrong data-end=\"4019\" data-start=\"3990\"\u003eincrease Ki-67 expression\u003c\/strong\u003e in aging vascular cell culture contexts, with promoter-region interaction explored via molecular docking. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4414\" data-start=\"4167\"\u003e\u003cstrong data-end=\"4186\" data-start=\"4167\"\u003eInterpretation:\u003c\/strong\u003e If reproducible, this would suggest Vesugen might partially restore endothelial renewal capacity in aging or stress models—\u003cstrong data-end=\"4317\" data-start=\"4310\"\u003ebut\u003c\/strong\u003e moving from cell culture marker changes to human clinical benefit is a major translational leap.\u003c\/p\u003e\n\u003chr data-end=\"4419\" data-start=\"4416\"\u003e\n\u003ch2 data-end=\"4478\" data-start=\"4421\"\u003e5) Pharmacokinetics (PK): what can be said responsibly\u003c\/h2\u003e\n\u003cp data-end=\"4594\" data-start=\"4479\"\u003eThere is \u003cstrong data-end=\"4522\" data-start=\"4488\"\u003eno authoritative drug-label PK\u003c\/strong\u003e for Vesugen. As an \u003cstrong data-end=\"4567\" data-start=\"4542\"\u003eunmodified tripeptide\u003c\/strong\u003e, general principles apply:\u003c\/p\u003e\n\u003cul data-end=\"5019\" data-start=\"4595\"\u003e\n\u003cli data-end=\"4667\" data-start=\"4595\"\u003e\n\u003cp data-end=\"4667\" data-start=\"4597\"\u003elikely \u003cstrong data-end=\"4635\" data-start=\"4604\"\u003erapid enzymatic degradation\u003c\/strong\u003e without protective formulation,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4730\" data-start=\"4668\"\u003e\n\u003cp data-end=\"4730\" data-start=\"4670\"\u003ehigh \u003cstrong data-end=\"4707\" data-start=\"4675\"\u003eroute\/formulation dependence\u003c\/strong\u003e for systemic exposure,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5019\" data-start=\"4731\"\u003e\n\u003cp data-end=\"5019\" data-start=\"4733\"\u003ethe bioregulator literature discusses transport and stability features for ultrashort peptides more broadly (e.g., transporter biology and resistance to hydrolysis for certain sequences), but this does not automatically define Vesugen’s human PK. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5024\" data-start=\"5021\"\u003e\n\u003ch2 data-end=\"5065\" data-start=\"5026\"\u003e6) Preclinical and clinical evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"5111\" data-start=\"5067\"\u003e6.1 Mechanistic \/ preclinical (stronger)\u003c\/h3\u003e\n\u003cul data-end=\"5513\" data-start=\"5112\"\u003e\n\u003cli data-end=\"5319\" data-start=\"5112\"\u003e\n\u003cp data-end=\"5319\" data-start=\"5114\"\u003e\u003cstrong data-end=\"5151\" data-start=\"5114\"\u003eEndothelial aging model evidence:\u003c\/strong\u003e vesugen reported to increase \u003cstrong data-end=\"5190\" data-start=\"5181\"\u003eKi-67\u003c\/strong\u003e in aging vascular endothelial cultures; promoter interaction explored computationally. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5513\" data-start=\"5320\"\u003e\n\u003cp data-end=\"5513\" data-start=\"5322\"\u003e\u003cstrong data-end=\"5363\" data-start=\"5322\"\u003eGene expression regulation framework:\u003c\/strong\u003e systematic review consolidates how short peptides can influence gene expression and differentiation programs. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"5572\" data-start=\"5515\"\u003e6.2 Human clinical evidence (weaker \/ not drug-grade)\u003c\/h3\u003e\n\u003cul data-end=\"6033\" data-start=\"5573\"\u003e\n\u003cli data-end=\"5802\" data-start=\"5573\"\u003e\n\u003cp data-end=\"5802\" data-start=\"5575\"\u003eBrochure claims of clinical effectiveness in complex treatment of atherosclerosis and vascular disease exist, but are not presented as fully transparent RCT datasets in those materials. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6033\" data-start=\"5803\"\u003e\n\u003cp data-end=\"6033\" data-start=\"5805\"\u003eA tripeptide neuroprotection review mentions occupational-cohort cognitive improvement with KED\/EDR; it’s a lead worth tracing to primary clinical publications if you need high confidence. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6038\" data-start=\"6035\"\u003e\n\u003ch2 data-end=\"6089\" data-start=\"6040\"\u003e7) Safety and tolerability: scientific framing\u003c\/h2\u003e\n\u003cp data-end=\"6249\" data-start=\"6090\"\u003eBecause Vesugen is not an FDA\/EMA-approved medicine in the typical markets where it is sold, there is \u003cstrong data-end=\"6248\" data-start=\"6192\"\u003eno standardized pharmacovigilance-grade safety label\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp data-end=\"6280\" data-start=\"6251\"\u003eKey real-world uncertainties:\u003c\/p\u003e\n\u003cul data-end=\"6717\" data-start=\"6281\"\u003e\n\u003cli data-end=\"6383\" data-start=\"6281\"\u003e\n\u003cp data-end=\"6383\" data-start=\"6283\"\u003e\u003cstrong data-end=\"6302\" data-start=\"6283\"\u003eIdentity\/purity\u003c\/strong\u003e variability across suppliers and product lines (especially “research peptides”).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6507\" data-start=\"6384\"\u003e\n\u003cp data-end=\"6507\" data-start=\"6386\"\u003e\u003cstrong data-end=\"6411\" data-start=\"6386\"\u003eImmunologic reactions\u003c\/strong\u003e are possible with peptide products (risk depends heavily on impurities, excipients, and route).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6717\" data-start=\"6508\"\u003e\n\u003cp data-end=\"6717\" data-start=\"6510\"\u003e\u003cstrong data-end=\"6548\" data-start=\"6510\"\u003eOff-target transcriptional effects\u003c\/strong\u003e are theoretically possible with any compound posited to modulate gene expression—this is precisely why controlled clinical development is required before strong claims.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6722\" data-start=\"6719\"\u003e\n\u003ch2 data-end=\"6750\" data-start=\"6724\"\u003e8) Regulatory landscape\u003c\/h2\u003e\n\u003cp data-end=\"6973\" data-start=\"6751\"\u003eVesugen is generally positioned as a \u003cstrong data-end=\"6835\" data-start=\"6788\"\u003ebioregulator\/supplement or research peptide\u003c\/strong\u003e, not as a regulated therapeutic with approved indications and harmonized manufacturing standards. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"6978\" data-start=\"6975\"\u003e\n\u003ch2 data-end=\"7047\" data-start=\"6980\"\u003e9) Future directions: what would validate Vesugen scientifically\u003c\/h2\u003e\n\u003cp data-end=\"7150\" data-start=\"7048\"\u003eIf Vesugen were to be advanced as a modern therapeutic-grade program, the decisive work would include:\u003c\/p\u003e\n\u003col data-end=\"7900\" data-start=\"7152\"\u003e\n\u003cli data-end=\"7273\" data-start=\"7152\"\u003e\n\u003cp data-end=\"7273\" data-start=\"7155\"\u003e\u003cstrong data-end=\"7186\" data-start=\"7155\"\u003eRigorous product definition\u003c\/strong\u003e\u003cbr data-end=\"7189\" data-start=\"7186\"\u003eConfirmed sequence (KED), impurity profile, stability, and reproducibility (GMP).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7464\" data-start=\"7275\"\u003e\n\u003cp data-end=\"7464\" data-start=\"7278\"\u003e\u003cstrong data-end=\"7302\" data-start=\"7278\"\u003eHuman PK\/PD bridging\u003c\/strong\u003e\u003cbr data-end=\"7305\" data-start=\"7302\"\u003eDemonstrate exposure and tissue engagement, with biomarker readouts (endothelial turnover signatures, transcriptomics, circulating endothelial cells, etc.).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7700\" data-start=\"7466\"\u003e\n\u003cp data-end=\"7700\" data-start=\"7469\"\u003e\u003cstrong data-end=\"7506\" data-start=\"7469\"\u003eMechanism-to-clinical translation\u003c\/strong\u003e\u003cbr data-end=\"7509\" data-start=\"7506\"\u003eMove beyond Ki-67: show endothelial functional outcomes (barrier integrity, NO signaling, microvascular perfusion metrics) and clinically relevant endpoints in defined patient populations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7900\" data-start=\"7702\"\u003e\n\u003cp data-end=\"7900\" data-start=\"7705\"\u003e\u003cstrong data-end=\"7735\" data-start=\"7705\"\u003eControlled clinical trials\u003c\/strong\u003e\u003cbr data-end=\"7738\" data-start=\"7735\"\u003eRandomized, blinded studies with validated vascular endpoints (e.g., flow-mediated dilation, microvascular function, imaging biomarkers) and safety monitoring.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"7905\" data-start=\"7902\"\u003e\n\u003ch2 data-end=\"7945\" data-start=\"7907\"\u003eSelected references (highest-yield)\u003c\/h2\u003e\n\u003cul data-end=\"8560\" data-start=\"7946\"\u003e\n\u003cli data-end=\"8068\" data-start=\"7946\"\u003e\n\u003cp data-end=\"8068\" data-start=\"7948\"\u003eVesugen and endothelial aging \/ Ki-67 promoter interaction (indexed abstract): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8190\" data-start=\"8069\"\u003e\n\u003cp data-end=\"8190\" data-start=\"8071\"\u003eSpringer paper on vesugen and Ki-67 expression during aging (indexed record): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8307\" data-start=\"8191\"\u003e\n\u003cp data-end=\"8307\" data-start=\"8193\"\u003ePDF describing vesugen vs D-7 experimental focus (methods\/aims visible): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8423\" data-start=\"8308\"\u003e\n\u003cp data-end=\"8423\" data-start=\"8310\"\u003eSystematic review on peptide regulation of gene expression (framework): \u003cspan data-state=\"closed\" class=\"\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8560\" data-start=\"8424\"\u003e\n\u003cp data-end=\"8560\" data-start=\"8426\"\u003eBioregulator brochure mentioning clinical-use positioning (context, not RCT-grade evid\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684841779538,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Vesugen20mg.png?v=1770834799","url":"https:\/\/sciencepeptideslab.com\/products\/vesugen-20mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}